Скачать или смотреть Should the federal government reschedule cannabis? Implications for marijuana use, research, policy

In late 2025, President Trump signed an Executive Order to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.

If finalized, the reclassification would mark a significant policy shift with concrete legal, economic, and research implications. What does this mean for recreational/medical use, state and federal drug law, and cannabis research?

A panel of experts moderated by Mason Marks, senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, brought multidisciplinary perspectives to this complicated issue.

Panelists:
Dr. Peter Grinspoon, Primary care physician, cannabis and addiction specialist, Massachusetts General Hospital; Instructor, Harvard Medical School
Ifetayo Harvey, executive director, People of Color Psychedelic Collective; POPLAR affiliated researcher, Petrie-Flom Center, Harvard Law School
Hirsh Jain ‘12, CEO, Ananda Strategy; vice chair, Cannabis Chamber of Commerce
Robert Mikos, professor, Vanderbilt Law School; POPLAR affiliated researcher, Petrie-Flom Center, Harvard Law School

0:00 Susanna Baruch introduction
3:15 Mason Marks introduction
5:00 Rob Mikos remarks
7:35 Peter Grinspoon remarks
9:35 Ifetayo Harvey remarks
10:55 Hirsh Jain remarks
13:25 Discussion and Q&A
59:48 Closing remarks

More on the Petrie-Flom Center: https://petrieflom.law.harvard.edu/
Learn about POPLAR: https://petrieflom.law.harvard.edu/th...
Visit Harvard Law Today: https://hls.harvard.edu/today/
Subscribe to the Harvard Law Today newsletter: https://hls.harvard.edu/sign-up-for-t...